Literature DB >> 15105150

Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.

David J Farrell1, David Felmingham.   

Abstract

Telithromycin MICs for 13,874 Streptococcus pneumoniae isolates collected in the first 3 years of the global PROTEKT study (1999 to 2003) were studied. There was no change in the distribution of telithromycin MICs over this period, even in countries where telithromycin is in use. The telithromycin MICs for 10 isolates (0.07%) were >/=4 micro g/ml, and these 10 isolates contained erm(B); there was no evidence of reproducible clonal spread between centers.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15105150      PMCID： PMC400575          DOI： 10.1128/AAC.48.5.1882-1884.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.

Authors:  T A Davies; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

Review 2.  The need for antimicrobial resistance surveillance.

Authors:  David Felmingham
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

3.  Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.

Authors:  David Felmingham; Ralf Rene Reinert; Yoichi Hirakata; Arne Rodloff
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

4.  Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.

Authors:  D J Farrell; I Morrissey; S Bakker; D Felmingham
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

5.  Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study.

Authors:  D J Farrell; S Douthwaite; I Morrissey; S Bakker; J Poehlsgaard; L Jakobsen; D Felmingham
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

6.  Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers.

Authors:  B Bozdogan; P C Appelbaum; L M Kelly; D B Hoellman; A Tambic-Andrasevic; L Drukalska; W Hryniewicz; H Hupkova; M R Jacobs; J Kolman; M Konkoly-Thege; J Miciuleviciene; M Pana; L Setchanova; J Trupl; P Urbaskova
Journal:  Clin Microbiol Infect       Date:  2003-07       Impact factor: 8.067

7.  Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Tsu-Lan Wu; Dine Yang; Wen-Kuei Huang; Jainn-Ming Shyr; Yin-Ching Chuang; Jen-Hsien Wan; Jing-Jou Yan; Jang-Jih Lu; Jiunn-Jong Wu; Wen-Chien Ko; Feng-Yee Chang; Yi-Chueh Yang; Yeu-Jun Lau; Yung-Ching Liu; Chun-Ming Lee; Hsieh-Shong Leu; Cheng-Yi Liu; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

8.  Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.

Authors:  Charles M Fogarty; Shigeru Kohno; Patricia Buchanan; Michel Aubier; Malik Baz
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790
  8 in total
  17 in total

1.  Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.

Authors:  M Rantala; S Huikko; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  Streptococcus pneumoniae isolates resistant to telithromycin.

Authors:  M Rantala; M Haanperä-Heikkinen; M Lindgren; H Seppälä; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.

Authors:  Adnan Al-Lahham; Peter C Appelbaum; Mark van der Linden; Ralf René Reinert
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

4.  Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.

Authors:  Ralf René Reinert; Mark van der Linden; Adnan Al-Lahham
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones.

Authors:  Diego Faccone; Patricia Andres; Marcelo Galas; Marta Tokumoto; Adriana Rosato; Alejandra Corso
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 6.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  A novel ketolide, RBx 14255, with activity against multidrug-resistant Streptococcus pneumoniae.

Authors:  V Samuel Raj; Tarani Kanta Barman; Vandana Kalia; Kedar Purnapatre; Smita Dube; Ramkumar G; Pragya Bhateja; Tarun Mathur; Tridib Chaira; Dilip J Upadhyay; Yogesh B Surase; R Venkataramanan; Anjan Chakrabarti; Biswajit Das; Pradip K Bhatnagar
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 8.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

Review 9.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Methylation of 23S rRNA nucleotide G748 by RlmAII methyltransferase renders Streptococcus pneumoniae telithromycin susceptible.

Authors:  Akiko Takaya; Yoshiharu Sato; Tatsuma Shoji; Tomoko Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.